Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Session: Breaking Ground: ID Clinical Trials

84 - Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin-Structure Infections

Thursday, October 17, 2024
11:00 AM – 11:15 AM US PT
Location: 404 AB
Disclosure(s):
Jessica Howard-Anderson, MD, MSc: No financial relationships to disclose
Toshimitsu Hamasaki, PhD: No financial relationships to disclose
Lizhao Ge, MAS: No financial relationships to disclose
Deborah Collyar, B.Sci: Apellis Pharmaceuticals, Inc.: Advisor/Consultant; Kinnate Biopharma: Advisor/Consultant
Sumathi Nambiar, MD MPH: Johnson and Johnson: Stocks/Bonds (Public Company)
Carol Hill, PhD: Glaxo SmithKline: Retirement Health, Cash Balance Plan, Stocks/Bonds (Public Company)
Holly S. Geres, BS: No financial relationships to disclose
Sara E. Cosgrove, MD, MS: No financial relationships to disclose
Thomas L. Holland, MD: Karius, Inc: Advisor/Consultant
Sarah B. Doernberg, MD, MAS: Basilea Pharmaceutica: Grant/Research Support; F2G Limited: Grant/Research Support; Genentech: Advisor/Consultant; Gilead Biosciences: Grant/Research Support; Janssen/J+J: Advisor/Consultant; Pfizer, Inc: Grant/Research Support; Regeneron, Inc: Grant/Research Support; Shinogi: Grant/Research Support
Henry Chambers, MD: Merck: Stocks/Bonds (Private Company); Moderna: Stocks/Bonds (Private Company)
Vance G. Fowler, MD, MHS: Affinergy: Advisor/Consultant; ArcBio: Stocks/Bonds (Private Company); Armata: Advisor/Consultant; Astra Zeneca: Advisor/Consultant, Grant/Research Support; Basilea: Advisor/Consultant, Grant/Research Support; ContraFect: Advisor/Consultant, Grant/Research Support; Debiopharm: Advisor/Consultant; Destiny: Advisor/Consultant; EDE: Grant/Research Support; Genentech: Advisor/Consultant, Grant/Research Support; GSK: Advisor/Consultant; Janssen: Advisor/Consultant; Karius: Grant/Research Support; MedImmune: Grant/Research Support; Merck: Grant/Research Support; sepsis diagnostics: Patent pending; UptoDate: Royalties; Valanbuio: Stocks/Bonds (Private Company), Stocks/Bonds (Private Company)
Scott R. Evans, PhD, M.S.: Abbvie: Advisor/Consultant (); Advantagene: Advisor/Consultant (); Akouos: Advisor/Consultant (); Apellis: Advisor/Consultant (); AstraZenenca: Advisor/Consultant (); BARDA: Advisor/Consultant (); Breast International Group: Advisor/Consultant (); CDC: Grant/Research Support (); Clover: Advisor/Consultant (); DayOneBio: Advisor/Consultant (); Degruyter: Editorial service (); Duke University: Advisor/Consultant (); Eli Lilly: Advisor/Consultant (); FDA: Advisor/Consultant (); Frontier Science Foundation: Board Member (); Genentech: Advisor/Consultant (); GSK: Advisor/Consultant (); Henry Jackson Foundation: Grant/Research Support (); International Drug Development Institute: Advisor/Consultant (); Johson & Johnson: Advisor/Consultant (); Medtronic: Advisor/Consultant (); NIH: Grant/Research Support (); Novartis: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Rakuten: Advisor/Consultant (); Roche: Advisor/Consultant (); Takeda: Advisor/Consultant (); Taylor & Francis: Book royalties (); Teva: Advisor/Consultant (); University of Penn: Advisor/Consultant (); Vir: Advisor/Consultant (); Wake Forest University: Advisor/Consultant (); Washington University: Advisor/Consultant ()
Helen Boucher, MD: ASM: Honoraria; Elsevier: Honoraria; Sanford Guide: Honoraria